Trial Profile
A Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System Metastases (CNS) From BRAF V600-Mutated Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 May 2022
Price :
$35
*
At a glance
- Drugs E 6201 (Primary) ; Dabrafenib
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Spirita Oncology; Strategia Therapeutics
- 05 Mar 2022 Status changed from recruiting to discontinued.
- 13 Nov 2018 The trial design has been changed from sequential to single group assignment. Also, Endpoints and treatment arms has been amended.
- 09 Jul 2018 Status changed from not yet recruiting to recruiting.